DPP

Transformable prodrug nanoplatform via tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy

68 views | Aug 04 2023

In this study, a dual-responsive polymersomal prodrug nanoplatform was developed, combining CAF inhibition, ROS consumption, immune checkpoint blockade, and immunogenic cell death induction, leading to improved tumor regression and long-term immune memory response, offering potential for effective cancer treatment. [Read the Full Post]

Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity

23 views | Apr 21 2023

Sitagliptin shows promise as a potential antiglioma drug to overcome TMZ resistance and enhance the therapeutic efficacy of GBM treatment. [Read the Full Post]

Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells

597 views | Jan 16 2019

Choi B et al. suggested that DPP-4 could serve as a potential therapeutic target to inhibit calcific aortic valve disease progression. [Read the Full Post]

AGI5198 is the first highly potent and selective mutant IDH1 inhibitor

3633 views | Mar 07 2014

AGI-5198, potently inhibits mutant IDH1 (R132H-IDH1 and R132C-IDH1), but not wildtype IDH1 (IC50 > 100 μM) or any of IDH2 isoforms (R140Q, R172K, wildtype) (IC50 > 100 μM) [Read the Full Post]

Tipifarnib is a farnesyltransferase inhibitor

2915 views | Dec 18 2013

Tipifarnib (R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. [Read the Full Post]

FK866 has been shown to induce apoptosis by non competitive

3216 views | Nov 12 2013

APO866 effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM. Phase 1/2. [Read the Full Post]

LY2484595 is one of two CETP inhibitors currently being evaluated

2917 views | May 02 2013

LY2484595 results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4 hours, 8 hours and 24 hours post dose respectively in human ApoAI and CETP double transgenic mice. [Read the Full Post]

MDV3100 is an androgen receptor antagonist

2603 views | Jan 15 2013

Increased protein levels and kinase activities of Src family kinases have been observed in a wide diversity of human cancers, including melanoma, breast, ovarian, and lung cancer . The prototype SFK is c-Src, MDV3100 which is a protein tyrosine kinase from which the oncogenic viral Src is derived . [Read the Full Post]